Senior Healthcare Executive Jimenez Apointed to the HepaLife Board of Directors
BOSTON - HepaLife Technologies, Inc. has appointed Javier Jimenez, a seasoned, senior medical device and healthcare executive with worldwide experience, to the Company’s Board of Directors.
“Mr. Jimenez brings a highly-accomplished executive background and much sought-after professional credentials to our team,” stated HepaLife President and CEO, Mr. Frank Menzler. “I very much look forward to drawing on Javier’s expertise as we advance the commercial development of our cell-based technologies, which continue to produce promising outcomes for key applications, including avian influenza vaccine development, in vitro toxicology testing, and the first-of-its-kind artificial liver device.
“Our cell technologies really stand out against traditional industry products, especially in the area of artificial liver device development,” continued Mr. Menzler. “HepaLife’s patented PICM-19 cells have shown a special capacity to grow at high densities and under conditions that would render other cell lines useless. Most importantly, unlike others, our cells do not become cancerous after repeated growth, and they consistently imitate the behavior of the liver, which makes them ideally suited for incorporation into an artificial liver device.”
In ongoing research, scientists have demonstrated that the Company’s PICM-19 cells have unique characteristics distinct from other cells, and are able to successfully mimic the liver’s response in several important ways. Among other research outcomes, important liver-specific activity levels in the PICM-19 cells were up to three times higher than those found in human-derived cell lines frequently used for similar applications.
This functionality is crucial, since according to researchers, the most vital component in an artificial liver device is not the mechanical hardware, but rather, it is the biological cells inside the device which are responsible for truly replicating and performing the functions of the human liver.
“It’s now more important than ever to build on our research success in the labs, all of which has transpired during the tenure of our outgoing Directors, Mr. Arian Soheili and Mr. Jasvir Kheleh,” continued Mr. Menzler. “I want to thank them for their management guidance and tireless efforts during our early research and development phase, and welcome aboard Mr. Javier Jimenez who joins us as HepaLife moves its technologies through the development path and towards commercialization.
“I’m eager to leverage Javier’s 15-plus years of leadership experience in the commercial medical device and healthcare arenas,” concluded Mr. Frank Menzler.
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.